Mesoblast to Present Half-Year Results as It Expands Global Cell Therapy Portfolio

Mesoblast Limited ( (AU:MSB) ) has issued an announcement.

Mesoblast, a dual-listed biotech on the ASX and Nasdaq, has pioneered mesenchymal stromal cell therapies, including Ryoncil, the first FDA-approved MSC treatment for pediatric steroid-refractory acute graft versus host disease. The company is expanding its remestemcel-L and rexlemestrocel-L platforms into additional indications such as adult SR-aGvHD, biologic-resistant inflammatory bowel disease, heart failure and chronic low back pain, supported by a broad global patent estate and proprietary large-scale manufacturing.

The company will host a webcast to present operational highlights and financial results for the half year ended December 31, 2025, offering investors an update on its progress and strategy. The live and archived event, accessible via its website, underscores Mesoblast’s efforts to engage stakeholders as it advances commercialization partnerships in key regions and seeks to scale global access to its off-the-shelf cell therapies.

The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.

More about Mesoblast Limited

Mesoblast Limited is a biotechnology company focused on developing allogeneic, off-the-shelf cellular medicines for severe and life-threatening inflammatory conditions. Its proprietary mesenchymal lineage cell therapy platform is designed to counter damaging inflammation across multiple immune pathways, and the company operates in major markets including Australia, the United States, Europe, Japan, China and Singapore.

Average Trading Volume: 4,118,850

Technical Sentiment Signal: Buy

Current Market Cap: A$3.15B

For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.